AnHorn Medicines Co., Ltd.
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
AnHorn’s flagship therapeutic modality is BIGPRO®, a bi‑functional ligand that induces targeted degradation of disease-causing proteins. Using their proprietary AIMCADD® platform (which integrates AI, bioinformatics, and medicinal chemistry), AnHorn rapid
The content above was translated by Ai
Founded Year
2020
Unified Business No.
83523270
Status
Active
Number of Employees
0
Total Paid-in
Capital
476,915,370 (NT$)
Location of Company
Taiwan
, Taipei City
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
AnHorn Medicines Co., Ltd., founded in 2020 and based in Taipei, is a biotech company that designs novel therapeutics using an AI-powered drug discovery platform (AIMCADD®). Their mission is to develop a new class of protein-degrading therapies (BIGPRO®) that selectively eliminate disease-causing proteins, targeting difficult-to-treat conditions such as cancer, neurodegenerative disorders, and age-related diseases.
The content above was translated by Ai
